Literature DB >> 12054692

RCAS1 is associated with ductal breast cancer progression.

Joel Rousseau1, Bernard Têtu, Danielle Caron, Patrick Malenfant, Paola Cattaruzzi, Marie Audette, Charles Doillon, Jacques P Tremblay, Benoit Guérette.   

Abstract

RCAS1/EBAG9 (receptor-binding cancer antigen expressed on SiSo cells/ estrogen receptor-binding fragment-associated gene 9), an estrogen-transcribed protein, has been shown to be expressed in a wide variety of cancers, including uterine, ovarian, and lung cancer cells. Soluble and membranous RCAS1 proteins may play a role in the immune escape of tumor cells by promoting T lymphocyte inhibition of growth and apoptosis. In the present report, the presence of RCAS1 was revealed in human ductal breast cancer biopsies by immunohistochemistry. Its cytoplasmic expression was exhibited in cancer cells obtained from tumor biopsies and in breast cancer cell lines. RCAS1 significantly correlated with tumor grade. In addition, RCAS1 was identified in MCF7 culture supernatants. Those observations suggest that RCAS1 is a new marker for breast cancer progression and a possible mechanism for breast cancer immune escape.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054692     DOI: 10.1016/S0006-291X(02)00401-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis.

Authors:  Su-xia Han; Jing Wang; Li-juan Wang; Gui-hua Jin; Xia Ying; Chen-chen He; Xi-jing Guo; Jian-ying Zhang; Ying Zhang; Qing Zhu
Journal:  Tumour Biol       Date:  2014-03-21

Review 2.  Peptide-displaying phage technology in glycobiology.

Authors:  Michiko N Fukuda
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

3.  Posterior Contraction Rates of the Phylogenetic Indian Buffet Processes.

Authors:  Mengjie Chen; Chao Gao; Hongyu Zhao
Journal:  Bayesian Anal       Date:  2015-06-05       Impact factor: 3.728

4.  Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells.

Authors:  Tiera A Liby; Perry Spyropoulos; Haley Buff Lindner; Juanita Eldridge; Craig Beeson; Tien Hsu; Robin C Muise-Helmericks
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

5.  Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.

Authors:  Madhumita Chatterjee; Saroj Mohapatra; Alexei Ionan; Gagandeep Bawa; Rouba Ali-Fehmi; Xiaoju Wang; James Nowak; Bin Ye; Fatimah A Nahhas; Karen Lu; Steven S Witkin; David Fishman; Adnan Munkarah; Robert Morris; Nancy K Levin; Natalie N Shirley; Gerard Tromp; Judith Abrams; Sorin Draghici; Michael A Tainsky
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer.

Authors:  K Leelawat; T Watanabe; M Nakajima; S Tujinda; C Suthipintawong; V Leardkamolkarn
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

7.  Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.

Authors:  Tatiana A Reimer; Ioannis Anagnostopoulos; Bettina Erdmann; Insa Lehmann; Harald Stein; Peter Daniel; Bernd Dörken; Armin Rehm
Journal:  BMC Cancer       Date:  2005-05-17       Impact factor: 4.430

8.  The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse.

Authors:  Magdalena Dutsch-Wicherek; Romana Tomaszewska; Agata Lazar; Lukasz Wicherek; Jacek Skladzien
Journal:  BMC Cancer       Date:  2009-01-28       Impact factor: 4.430

Review 9.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

10.  The analysis of RCAS1 and DFF-45 expression in nasal polyps with respect to immune cells infiltration.

Authors:  Magdalena Dutsch-Wicherek; Romana Tomaszewska; Pawel Strek; Lukasz Wicherek; Jacek Skladzien
Journal:  BMC Immunol       Date:  2006-03-21       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.